Home > Boards > US Listed > Biotechs > Cel-Sci (CVM)

To the moon!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
learning curve Member Profile
 
Followed By 35
Posts 7,824
Boards Moderated 0
Alias Born 02/15/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/7/2021 3:25:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2021 10:51:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2021 10:49:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/7/2021 10:45:24 AM
CEL-SCI says analysis of successful study arm was pre-specified in protocol Seeking Alpha - 7/7/2021 9:48:00 AM
CEL-SCI Corporation Issues Letter to Shareholders Business Wire - 7/7/2021 8:00:00 AM
CEL-SCI extends gains despite discussion on cancer trial Seeking Alpha - 7/2/2021 11:53:24 AM
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available Business Wire - 7/2/2021 11:20:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/2/2021 6:01:17 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 9:13:04 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2021 9:06:14 AM
Ocuphire Pharma, Predictive Oncology leads healthcare gainers; Altimmune, electroCore among major losers Seeking Alpha - 6/30/2021 11:03:36 AM
CEL-SCI to further discuss late-stage Multikine data in head and neck cancer Seeking Alpha - 6/30/2021 10:59:10 AM
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021 Business Wire - 6/30/2021 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/29/2021 10:55:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/29/2021 8:30:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/28/2021 4:35:17 PM
CEL-SCI plummets 43% after phase 3 immunotherapy data misses primary endpoint Seeking Alpha - 6/28/2021 11:43:58 AM
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiv... Business Wire - 6/28/2021 9:20:00 AM
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting Business Wire - 6/25/2021 8:30:00 AM
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering Business Wire - 6/11/2021 11:49:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/9/2021 4:09:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/9/2021 4:08:50 PM
CEL-SCI down 11% on $31.7M capital raise Seeking Alpha - 6/9/2021 3:56:17 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/9/2021 6:05:04 AM
learning curve   Friday, 05/07/21 03:26:04 PM
Re: None
Post # of 40243 
To the moon!

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences